Lataa...

Engaging the lysosomal compartment to combat B cell malignancies

The combination of rituximab, a type I anti-CD20 mAb, with conventional chemotherapy has significantly improved the outcome of patients with B cell malignancies. Regardless of this success, many patients still relapse with therapy-resistant disease, highlighting the need for the development of mAbs...

Täydet tiedot

Tallennettuna:
Bibliografiset tiedot
Päätekijät: Grønbæk, Kirsten, Jäättelä, Marja
Aineistotyyppi: Artigo
Kieli:Inglês
Julkaistu: American Society for Clinical Investigation 2009
Aiheet:
Linkit:https://ncbi.nlm.nih.gov/pmc/articles/PMC2719949/
https://ncbi.nlm.nih.gov/pubmed/19620776
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1172/JCI40259
Tagit: Lisää tagi
Ei tageja, Lisää ensimmäinen tagi!